$ALMS

2 theses

bullish 100%neutral 0%bearish 0%

Avg return (1w)

-14.3%

Win rate (1w)

0% (2 resolved)

1d 3d 1w 1m 3m 6m 1y

Past performance does not predict future results. Informational only, not investment advice.

Recent theses

Prices delayed ~15 min · refreshed 28m ago

$ALMSSEC Form 4bullish

AKKARAJU SRINIVAS · ALUMIS INC. · 23d agono track record yet

Long 986,721 shares of ALMS

Bought 986,721 @ $10.87 avg · $10,726,255 · 2026-09-04

Form 4: AKKARAJU SRINIVAS bought ALMS

AKKARAJU SRINIVAS (Director at ALUMIS INC.) reported an open-market purchase of 986,721 shares of ALMS at an average $10.87, roughly $10,726,255, in a Form 4 filed 2026-09-09.

At post $9.80Now $6.95-29.1% since posted28m ago

1d+1.0%

3d-6.3%

1w-19.0%

1m—

3m—

6m—

1y—

View filing on SEC.gov →

$ALMSSEC 13Dbullish

Foresite Capital Fund VI LP · beneficial owner of Latigo Biotherapeutics, Inc. · 46d agono track record yet

Long 9,181,328 shares of ALMS

9,181,328 shares · 14.5% of class · 2026-08-10

Schedule 13D: Foresite Capital Fund VI LP disclosed a stake in ALMS

Foresite Capital Fund VI LP disclosed a 14.5% stake of 9,181,328 shares in Latigo Biotherapeutics, Inc. (ALMS) in a Schedule 13D filed 2026-08-17.

At post $25.50Now $6.95-72.8% since posted28m ago

1d-2.4%

3d-10.4%

1w-9.7%

1m-68.9%

3m—

6m—

1y—

View filing on SEC.gov →

End of results.